S&P 500Dow JonesNASDAQ 100DAX 40MDAXSDAXTecDAXATXSMICAC 40AEXBEL 20IBEX 35
Home/S&P 500/Kenvue
Kenvue

Kenvue

KVUES&P 500
19,29 $
Dividend yield2,10 %
Continuity4 yr
Dividend0,42 $
DiviScore
40SCORERisk
Performance2/35
Dividend Quality19/35
AGM Date
Ex-Date
13.05.2026
Payment
CAGR 3Y
-8.7%

€10,000 invested in 2023 · with dividend reinvestment

+-17%
End Value
8.292,69 $
Total Return
+-17.1%
Annual Return
-5.7% p.a.
Dividends Received
868,17 $

Dividend history

4 years continuous
YearAmountDividend yieldAGM dateEx-datePayment dateChange
20260,42 $13.05.2026-49.6%
20250,83 $12.11.2025+2.0%
20240,81 $13.11.2024+305.0%
20230,20 $07.11.2023

About Kenvue

Kenvue is the consumer-health company spun off from Johnson & Johnson, home to household names such as Tylenol, Band-Aid, Listerine, Neutrogena and Aveeno. It holds leading positions in over-the-counter medicines, skin health and personal care, categories that are generally stable but competitive and sensitive to consumer spending and private-label pressure. As a recently independent company, Kenvue has only a short dividend history, though it launched its payout at a meaningful level, giving it a moderate yield from the start. Its dividend-focused score is held back by the brief track record and the litigation and margin questions the business faces. The distribution looks affordable, but investors have limited history to judge its consistency and growth potential.

Frequently Asked Questions

The next payment date is not yet announced.
Kenvue has a DiviScore of 40/100. DiviScore rates dividend stocks based on price performance, dividend quality, fundamentals, and stability.
Kenvue's current dividend yield is 2.10% based on the latest dividend.
Kenvue (KVUE) is a member of S&P 500. Current data including price, dividend, and DiviScore is updated daily.
DiviScore is a proprietary 100-point rating based on four pillars: Performance (35 pts), Dividend Quality (35 pts), Fundamentals (15 pts), and Stability (15 pts). It simulates a 10-year investment with automatic dividend reinvestment.